End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.98 EUR | -1.00% |
|
-1.00% | -1.00% |
Jun. 17 | Neovacs: collaboration agreement with CNRS | CF |
Jun. 10 | Neovacs: presents results from vaccine candidates | CF |
Business Summary
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapy
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +47,868.71% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +47,868.71% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 20-09-30 | |
Vincent Serra
COO | Chief Operating Officer | 55 | 19-02-19 |
Charlène Masson
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 85 | 03-05-27 | |
Daniel Zagury
FOU | Founder | - | 93-04-15 |
Hugo Brugière
CEO | Chief Executive Officer | - | - |
Baudouin Hallo
BRD | Director/Board Member | - | - |
Muriel Haim
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 140 | 0 ( 0.1248 %) | 0 | 0.1248 % |
Company contact information
![address NEOVACS(ALNEV)](https://cdn.zonebourse.com/static/address/6076410.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ALNEV Stock
- ALNEV Stock
- Company NEOVACS